Skip to main content

Table 2 Drug Compliance (N = 52)

From: A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study

Discontinuation Day

No. of Patients

Completion Rate (%)

Reason for Discontinuation

 

52

100

 

5

51

98.1

Grade 1 anorexia (Patient refusal)

5

50

96.2

Grade 2 malaise (Patient refusal)

42

49

94.2

Recurrence

47

48

92.3

Grade 1 diarrhea (Patient refusal)

134

47

90.4

Grade 3 elevation of AST or ALT

141

46

88.5

Grade 3 elevation of total bilirubin

171

45

86.5

Patient refusal

217

44

84.6

Patient refusal

245

43

82.7

Grade 3 body weight loss

267

42

80.8

Grade 2 elevation of AST or ALT

311

41

78.8

Grade 3 malaise

321

40

76.9

Grade 2 dry skin

403

39

75.0

Grade 2 nausea (Patient refusal)

455

38

73.1

Grade 2 pain of skin (Herpes zoster)

505

37

71.2

Grade 2 interstitial pneumonia

682

36

69.2

Patient refusal